ArticleJournal of neuroimmunology2008
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype.
Article in Journal of neuroimmunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Active Vaccination Strategies for Alzheimer's Disease: An Expanded Review.European journal of immunology · 2026Review
- Research progress on Alzheimer's disease vaccines: from Aβ-targeted approaches to clinical translation.Frontiers in aging · 2026Review
- Vaccines for Alzheimer's disease: a brief scoping review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model.Cancers · 2022Article
- Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.Cell reports · 2022Article
- Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.Neurobiology of disease · 2020Review
- Efficacy and Safety of the Immunization with DNA for Alzheimer's Disease in Animal Models: A Systematic Review from Literature.Journal of Alzheimer's disease reports · 2017Article
- MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency.Neurobiology of aging · 2017Article
- Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Article
- A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta.Neural regeneration research · 2013Article
- Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.Human vaccines & immunotherapeutics · 2013Article
- Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.Cellular and molecular neurobiology · 2011Article
- Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.Human gene therapy · 2010Article
- Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.Vaccine · 2010Article
- Amyloid-beta immunotherapy for Alzheimer's disease.CNS & neurological disorders drug targets · 2010Review
- Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.CNS & neurological disorders drug targets · 2010Review
- C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.Immunology letters · 2010Article
- Can Alzheimer disease be prevented by amyloid-beta immunotherapy?Nature reviews. Neurology · 2010Review
- DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.Gene therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
We have engineered a DNA epitope vaccine that expresses 3 self-B cell epitopes of Abeta(42) (3Abeta(1-11)), a non-self T helper (Th) cell epitope (PADRE), and 3 copies of C3d (3C3d), a component of complement as a molecular adjuvant, designed to safely reduce CNS Abeta. Immunization of mice with 3Abeta(1-11)-PADRE epitope vaccine alone generated only moderate levels of anti-Abeta antibodies and a pro-inflammatory T helper (Th1 phenotype) cellular immune response. However, the addition of 3C3d to the vaccine construct significantly augmented the anti-Abeta humoral immune response and, importantly, shifted the cellular immune response towards the potentially safer anti-inflammatory Th2 phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.